MARGARET WALLACE: Open Payments
NPI 1124475439 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,469 in 95 payments from 24 companies in 2025. Trend: 2023 $1,814 · 2024 $1,193 · 2025 $1,469
Food & beverage: $1,469
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $283 |
| Lilly USA, LLC | 19 | $248 |
| PFIZER INC. | 12 | $164 |
| Lundbeck LLC | 6 | $99 |
| AstraZeneca Pharmaceuticals LP | 4 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 3 | $67 |
| Novo Nordisk Inc | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Currax Pharmaceuticals LLC | 3 | $42 |
Products named: MOUNJARO, REXULTI, VRAYLAR, NURTEC ODT, UBRELVY, CAPLYTA, QULIPTA, AUSTEDO XR.
Industry payments across NE — which companies pay providers there.
